
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Privacy, Pediatrics, and Policy
FDA proposals for expanding the pediatric study program include tax incentives and }transferable exclusivity.}
Advertisement
Articles in this issue
almost 25 years ago
Research: New Horizonsalmost 25 years ago
Earnings: Tough Times Aheadalmost 25 years ago
Outbreak: Anthrax Alarmalmost 25 years ago
Patents: China on the Genome Mapalmost 25 years ago
Lilly's International Familyalmost 25 years ago
Update: Punishment and Reprievealmost 25 years ago
Shortage: Vaccine Worriesalmost 25 years ago
Gateway to Japanalmost 25 years ago
SurroundedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
Pharma Companies Raise List Prices, Including 16 That Had Agreements to Lower Prices with Trump Administration: Report
3
Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb
4
Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma
5




